The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements by Scheinberg, Phillip et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/90176/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Scheinberg, Phillip, Melenhorst, Jan J., Hill, Brenna J., Keyvanfar, Keyvan, Barrett, A. John, Price,
David and Douek, Daniel C. 2007. The clonal composition of human CD4+CD25+Foxp3+ cells
determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements.
Journal of Immunological Methods 321 (1-2) , pp. 107-120. 10.1016/j.jim.2007.01.005 file 
Publishers page: http://dx.doi.org/10.1016/j.jim.2007.01.005
<http://dx.doi.org/10.1016/j.jim.2007.01.005>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
The clonal composition of human CD4+CD25+Foxp3+ cells 
determined by a comprehensive DNA-based multiplex PCR for 
TCRB gene rearrangements
Phillip Scheinberg1, Jan J. Melenhorst1, Brenna J. Hill2, Keyvan Keyvanfar1, A. John 
Barrett1, David A. Price2,3, and Daniel C. Douek2
1Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 
Bethesda, MD
2Human Immunology Section, Vaccine Research Center, National Institute of Allergy and 
Infectious Diseases, National Institutes of Health, Bethesda, MD
3Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford 
OX3 9DS, UK
Abstract
The characterization of the T-cell receptor (TCR) repertoire of CD4+ regulatory T cells (TR) have 
been limited due to the RNA degradation that results following permeabilization and fixation as 
routinely used for intracellular staining of Foxp3. In the present study the clonal composition of 
human umbilical cord blood (UCB) and adult peripheral blood mononuclear cells (PBMC) CD4+ 
TR and non-TR was characterized by a DNA-based multiplex PCR which allowed for the 
consistent clonotypic characterization of cells that have undergone fixation and permeabilization. 
To validate this method, CD8+ T cells from two HLA A*0201 individuals were sorted and 
compared clonotypically based upon their ability either to secrete interferon-ś in response to a 
CMV pp65 epitope or to bind to the corresponding pMHC I tetramer. In the UCB and PBMCs 
clonotypes shared between the CD4+CD25+Foxp3+ and CD4+CD25+Foxp3− was observed in all 
3 UCB and in one adult PBMCs, suggesting that naïve and memory CD4+ TR can share the same 
clonotypes as CD4+ non-TR in humans.
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1. Introduction
In recent years CD4+CD25+ T cells have been recognized as an integral part of the cellular 
immune system, providing regulatory functions in tumor-specific, autoreactive and 
alloimmune responses in animal models and in humans (Edinger et al., 2003; Trenado et al., 
2003; Curiel et al., 2004; Ehrenstein et al., 2004; Viglietta et al., 2004; Viguier et al., 2004). 
Expression of the high affinity IL-2 receptor ř chain (CD25) has served as a phenotypic 
surface marker for these CD4+ regulatory T cells (TR) (Sakaguchi et al., 1995). However, in 
isolation, this discriminator has proven insufficient because CD25 is expressed as a 
consequence of activation in non-regulatory CD4+ T cells. More recently, the identification 
of TR cells has been better defined by expression of the forkhead family transcription factor 
P3 (Foxp3), which is required for the development and function of these cells (Hori et al., 
2003; Ramsdell, 2003). Foxp3 identification, either by real time PCR or by flow cytometry 
using Foxp3-specific monoclonal antibodies (Roncador et al., 2005) has permitted a more 
accurate segregation of regulatory and non-regulatory T cells within the CD4+CD25+ 
subset.
Such analyses do not however define the origin and antigen specificity of human TR cells 
which remains obscure as does the diversity of their T-cell receptor (TCR) repertoire. To 
examine these issues in more detail in humans, we aimed to assess and compare the clonal 
composition of CD4+CD25+ TR and non-TR cell populations identified by flow cytometry.
The identification of CD4+CD25+Foxp3+ cells by flow cytometry requires permeabilization 
and fixation for intracellular staining (ICS) of Foxp3. Under these conditions RNA is 
extremely vulnerable to degradation; thus, the integrity of the RNA template is 
compromised and cannot be used reliably for RNA-based molecular analysis. Thus, a 
genomic DNA-based PCR that allows for the characterization of T-cell clonotypes in non-
viable cell populations is a pre-requisite for the study of TR cell clonality.
As the combinatorial diversity of the T-cell receptor Ś-chain (TCRB) gene is extensive 
(Arstila et al., 2000), the design of primers to include all possible rearrangements has been 
challenging. Towards this goal, the European BIOMED-2 collaborative study developed 
DNA-based multiplex PCR assays for the detection of rearranged TCRB genes in 
lymphoproliferative disorders (van Dongen et al., 2003); consensus primers including all 
known functional TCRBV and TCRBJ regions were designed. Based on the experience of the 
BIOMED-2 collaborative study investigators and others (van Dongen et al., 2003; Du et al., 
2006), we designed and optimized a heminested multiplex PCR assay that allows for 
consistent characterization of TCRB complementarity determining region 3 (CDR3) 
sequences in cells isolated on the basis of parameters that are incompatible with cellular 
viability, such as intracellular cytokine production. This approach was then used to study the 
baseline clonality of naïve and memory TR and non-TR CD4+ T cells in unstimulated adult 
peripheral blood mononuclear cells (PBMCs) and umbilical cord blood cells (UCBCs).
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2. Materials and methods
2.1. Samples
Adult PBMCs were prepared from venous blood by density gradient centrifugation. UCBCs 
was provided by the New York Blood Center and were enriched for T cells by negative 
selection with the MIDI-magnetic cell sorting (Miltenyi Biotec, Auburn, CA, USA) protocol 
provided by the manufacturer. Frozen PBMCs and UCBC were thawed and washed prior to 
staining. All PBMC donors gave written permission for their blood to be used for research 
under Institutional Review Board– approved National Heart, Lung, and Blood Institute stem 
cell allotransplantation protocols.
2.2. Peptide-major histocompatibility complex class I (pMHCI) tetrameric complexes
Tetrameric recombinant pMHCI antigens for the HLA A*0201-restricted CMV pp65-
derived epitope (NLVPMVATV; residues 495– 503) used in this study were produced as 
described previously (Hutchinson et al., 2003). Once prepared, tetramers were stored in the 
dark at 4°C.
2.3. Cell stimulation for CMV responses
HLA A*0201-restricted CD8+ T cells specific for CMV pp65495– 503 were identified directly 
ex vivo with cognate fluorescent pMHCI tetramers (Price et al., 2005) and by antigen-
induced interferon-ś (IFN-ś) expression in parallel experiments, then sorted by flow 
cytometry. Tetramer stains were performed at 37°C for 20 min as described previously 
(Whelan et al., 1999). Antigenic peptide stimulation was performed with PBMCs as 
previously described (Pitcher et al., 1999; Betts et al., 2000). Briefly, CMV pp65495– 503 
peptide was used to stimulate cognate T cells in the presence of costimulatory mAbs (anti-
CD28 and anti-CD49d; 1 μg/ml final concentration) and brefeldin A (10 μg/ml; Sigma) 
overnight at 37°C. A negative control (costimulatory mAbs alone) was included in all 
experiments to quantify spontaneous production of effector cytokines.
2.4. Immunofluorescence staining
PBMCs were stained with directly conjugated mAbs specific for surface and intracellular 
markers (Becton Dickinson Immunocytometry Systems [BDIS], San Jose, CA) for 30 min at 
4°C. Surface stains were performed prior to, and intracellular stains subsequent to, fixation/
permeabilization for 10 min. Cells were washed and resuspended in 1% paraformaldehyde 
(PFA) in phosphate-buffered saline on completion of the staining procedure except in the 
case of tetramer-based viable cell sorts. PBMCs stimulated overnight with the pp65495– 503 
peptide were stained with conjugated mAbs specific for CD3, CD4, CD8 and interferon-ś. 
CMV-specific CD8+ T cells were identified by surface staining with CMV pp65495– 503 
tetramer, CD3 and CD8. Unstimulated adult PBMCs and UCBCs were stained with 
conjugated mAbs specific for CD3, CD4, CD25, and Foxp3 (BioLegend, San Jose, CA). 
Fluorescein isothiocyanate (FITC), Alexa 488, phycoerythrin (PE), peridinin chlorophyll 
protein (PerCP), allophycocyanin (APC) and phycoerythrin-Cy5 (PE-Cy5) were used as the 
fluorophores. FITC, PE and APC were used as fluorophores. BDIS solution was used for the 
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detection of intracellular cytokine and the Biolegend fixation/permeabilization kit was used 
for the Foxp3 intracellular staining.
2.5 Flow cytometric analysis
Four-parameter flow cytometric analysis was performed using a FACSCalibur flow 
cytometer (BDIS). At least 100,000 live CD3+ lymphocytes were collected for each 
experimental condition. The list mode data files were analyzed using FlowJo software (Tree 
Star, Inc., San Carlos, CA).
2.6. Flow cytometric cell sorting
All sorts were performed on stained cells fixed with 1% PFA using a FACS Aria (BDIS) or 
a FACSVantage SE Diva (BDIS) with the exception of tetramer sorted cells which were not 
fixed. Tetramer binding CMV-specific CD8+ T cells were sorted into RNAlater (Ambion, 
Austin, TX, USA); CD8+ T cells expressing IFN-ś after overnight incubation with the 
pp65495– 503 peptide were sorted into a dry collection tube. Unstimulated adult PBMCs and 
UCBCs were sorted based upon expression of CD25+ and/or Foxp3+ on CD3+CD4+ gated 
cells. Three populations were studied in each sample: CD25+Foxp3−; CD25+Foxp3+; and 
CD25−Foxp3+. A 3-way sort into a dry collection tube was performed and the cell pellets 
were then frozen at −80°C. Instrument set-up in all cases was performed according to the 
manufacturer’ s instructions. Instrument compensation was performed with antibody capture 
beads (BD Pharmingen) stained singly with individual antibodies used in the test samples.
2.7 RNA-based clonotypic assay
Clonotypes in the tetramer-sorted populations were identified using a strand-switch–
anchored reverse transcriptase polymerase chain reaction (RT-PCR) that amplifies all 
expressed TCRB gene products without bias (Douek et al., 2002; Price et al., 2004). Briefly, 
mRNA was extracted from the sorted antigen-specific T cells (Oligotex kit, Qiagen, 
Valencia, CA, USA). Amplification of TCRB CDR3 sequences was performed by using a 
modified version of the SMART procedure (switching mechanism at the 5′ end of RNA 
transcript) to generate cDNA followed by a template-switch anchored RT-PCR with a 3′ C-
region primer. The PCR product was gel purified and ligated into the pGEMT Easy vector 
(Promega, Madison, WI, USA) and used to transform Escherichia coli. Individual colonies 
were selected, amplified by PCR with M13 primers, and then sequenced to obtain TCRB 
CDR3 sequences.
2.8. Multiplex DNA-based clonotypic assay
The consensus primers for the multiplex PCR were based on the BIOMED-2 Concerted 
Action and were designed to cover all functional TCRBV and TCRBJ gene segments and to 
be compatible with multiplex PCR reactions (van Dongen et al., 2003). In order to minimize 
primer dimerization and allow for amplification of CDR3 sequences from low cell numbers, 
we designed an external set of TCRBJ primers and performed a heminested touchdown 
PCR. These primers were tested with all 23 TCRBV and internal TCRBJ primer set to ensure 
that primer dimerization or cross-priming did not occur. The final primer set was divided 
into 3 tubes: tube A contained all 23 TCRBV and 6 TCRBJ primers (1.1 –  1.6); tube B 
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contained all 23 TCRBV and 4 TCRBJ primers (2.1, 2.3, 2.4 and 2.5); and tube C contained 
all 23 TCRBV and 3 TCRBJ primers (2.2, 2.6 and 2.7). The TCRBV and TCRBJ primers used 
for each PCR reaction are shown in Table 1. This approach allowed for a significant 
reduction in primer dimerization and crosspriming, as well as a substantial decrease in 
nonspecific amplification. Specific bands of 250– 300 bp in size that contained TCRB CDR3 
sequences were consistently obtained. Sorted T cells were lysed in 100 μg/mL proteinase K 
(Boehringer, Indianapolis, IN) for 1 hr at 56°C and then 10 min at 95°C. PCR conditions 
were as follows: 1 × HiFi Buffer, 3mM MgSO4, 200 μM dNTPs, 0.056 U platinum Taq Hi-
Fi DNA polymerase (Invitrogen, Carlsbad, CA) and 10 pmol of each primer in a final 
volume of 50 μL. Touchdown PCR was run with the following cycling conditions: 95°C for 
30 sec, 68°C for 30 sec for 2 cycles; 95°C for 30 sec, 65°C for 30 sec and 68°C for 30 sec 
for 3 cycles; 95°C for 30 sec, 60°C for 30 sec and 68°C for 30 sec for 30 cycles. All samples 
were preactivated for 5 min at 95°C. The product of the first PCR was purified (Qiagen, 
Valencia, CA) and used as a template in the second PCR. The final PCR product was 
purified, ligated and transformed as detailed above for the RNA-based clonotype assay. PCR 
conditions and cycling parameters were identical for both PCR reactions. For clonotype 
classification the International Immunogenetics Information System (IMGT) nomenclature 
is used (Lefranc, 2004).
3. Results
3.1. Validation of the multiplex PCR
The development of a reliable multiplex PCR for TCRB gene rearrangements would enable 
clonotypic analysis of T cell populations where the integrity of the RNA is compromised 
such as in cells subjected to intracellular staining protocols or when amplicon size is small 
as in archived formalin-fixed tissue. Towards this goal, we developed a heminested 
multiplex DNA-based PCR as described in Materials and Methods. To validate this assay, 
we examined the functional antigen-specific CD8+ T-cell repertoire recruited in two CMV 
seropositive HLA A*0201+ individuals after stimulation with the CMV pp65495– 503 peptide 
and flow cytometric sorting on the basis of IFN-ś expression using the multiplex PCR. In 
tandem, we sorted viable CD8+ T cells of the same specificity identified physically with the 
corresponding pMHCI tetramer and examined clonality according to the well established 
RNA-based strand-switch RT-PCR protocol (Figure 1). In our experience, CD8+ T cell 
responses to this pMHCI antigen are generally oligoclonal (Price et al., 2005) and this 
system thus provides a rigorous test of assay specificity. Within each individual, the 
clonotypes identified in the CD8+ T cell populations specific for CMV pp65495– 503 using 
these two distinct approaches were highly comparable (Table 2). In separate experiments, 
unstimulated PBMCs were analyzed using the multiplex PCR and a polyclonal repertoire 
was observed as expected (data not shown). Furthermore, the TCRBJ genes identified in 
tubes A, B and C corresponded only to the respective TCRBJ primers added to each PCR 
reaction; thus, only TCRBJ 1.1 –  1.6 were present in the PCR product from tube A, only 
TCRBJ 2.1, 2.3, 2.4 and 2.5 were present in tube B, and only TCRBJ 2.2, 2.6 and 2.7 were 
present in tube C.
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3.2. Repertoire of Foxp3 CD4+ T cells in adult PBMCs and UCBCs
Three separate sets of unstimulated adult PBMCs and three UCBCs were analyzed for 
Foxp3 and/or CD25+ expression in CD4+ T cells by flow cytometry (Figure 2). At least 
1,000 cells were sorted from each of the following CD4+ T cell populations: 
CD25+Foxp3−, CD25+Foxp3+ and CD25−Foxp3+. A 250– 300 bp band was obtained for 
all sorted populations following the heminested PCR, as illustrated in Figure 3. Repertoire 
analysis of all 3 sorted populations both in the UCBCs and adult PBMCs demonstrated 
substantial diversity and polyclonality. Molecular clonotyping data from each of the sorted 
populations from UCBCs are shown on tables 3– 5 and of PBMC are shown on Tables 6– 8. 
Although all the populations analyzed were polyclonal, the same clonotype was identified at 
least once in the CD25+Foxp3− and CD25+Foxp3+ sorted cells from all 3 UCB samples 
and in one of the 3 adult PBMC samples (Table 9).
4. Discussion
The mechanism of immune suppression by CD4+ TR cells is poorly understood but it 
appears to be antigen-independent with a requirement for cell-cell contact (Sakaguchi, 
2004). However, the clonal composition of CD4+ TR cells and their corresponding antigen 
specificity remains obscure. The basis for the identification CD4+ TR cells by flow 
cytometry has been the high level of CD25 expression by these cells. Although the 
CD4+CD25hi T cell subset include the majority of Foxp3+ cells, CD4+ TR cells can express 
no or low levels of CD25 and recent studies have suggested that the downregulation of the 
IL-7 receptor (CD127) or the isolation of CD45RA+ naïve CD4+CD25high may serve as a 
discriminator between TR and non-TR CD4+ T cells (Hoffmann et al., 2006; Liu et al., 2006; 
Seddiki et al., 2006) without the need for ICS. However, the CD127 molecule may be 
downregulated upon T-cell activation and therefore, a consensus in which surface marker(s) 
can reliably and consistently identify human TR is lacking. Thus, the expression of Foxp3 by 
ICS remains the most precise method for the flow cytometric identification of CD4+ TR 
cells.
The study of the clonal composition of human CD4+ TR has been hampered by unreliable 
methods for the identification of these cells and by methodological limitations which 
prevented the reliable characterization of TCRB CDR3 region of permeabilized and fixed 
cells. In mice the repertoire of CD25+ and CD25−CD4+ T cells has been shown to be 
equally diverse with minimal overlap of TCRř sequences between the two populations 
(Hsieh et al., 2004; Hsieh et al., 2006) suggesting that regulatory and non-regulatory CD4+ 
T cells in the mouse originate in the thymus as separate lineages. In humans the clonal 
composition of CD4+ TR has not been characterized clonotypically, but clonal homology 
between TR and non-TR CD4+ T cell subsets was addressed indirectly in a recent study 
where similar expansions in VŚ2 was observed in CD4+CD25− and CD4+CD25hi subsets 
and in the CD4+Foxp3− and CD4+Foxp3+ subsets after stimulation with CMV lysate 
(Vukmanovic-Stejic et al., 2006).
Previously published methods for DNA-based PCR approaches are time-consuming, require 
multiple tubes with panels of family-specific primers or use highly degenerate consensus 
primers which limit the number of detectable rearrangements (Rosenberg et al., 1992; Kneba 
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et al., 1995; Assaf et al., 2000; Du et al., 2006). Our initial experience with the method 
proposed by the BIOMED-2 investigators was confounded by frequent primer dimerization 
and amplification of non-specific products, some of which were observed within the 
expected size range for true TCR amplicons. These problems occurred particularly in cases 
where the number of analyzed cells was low, posing additional limitations for certain 
applications. To overcome these issues, we developed a heminested approach and resolved 
problematic primer combinations with the addition of a third PCR tube; these modifications 
significantly improved the methodology allowing for a more efficient PCR reaction with 
elimination of primer dimerization and non-specific bands.
As reliable antibodies for the identification of Foxp3 expression by flow cytometry became 
available recently, we chose to use our modified DNA-based multiplex PCR to analyze the 
TCR repertoire of CD4+CD25+Foxp3+ cells in UCB and adult PBMC; 
CD4+CD25+Foxp3− and CD4+CD25−Foxp3+ populations were analyzed in parallel as 
comparators. Our data show that the repertoire of unstimulated CD4+ TR cells in UCB and 
PBMCs is highly polyclonal and that, on occasion, the same TCRs can be expressed in both 
CD4+CD25+Foxp3+ and CD4+CD25+Foxp3− populations. The latter observation suggests 
an ontogenetic relationship between the CD4+CD25+Foxp3+ and CD4+CD25+Foxp3− 
populations that might relate to separate differentiation pathways after encounter with the 
same cognate antigen or to a common origin in the thymus. Further studies of antigen-
specific CD4+ T cells are required to distinguish between these and other possibilities.
In summary, we have developed a practical and reliable multiplex DNA-based PCR for 
TCRB gene rearrangements that can be used to examine the clonal composition of T cell 
populations in which the RNA has been degraded. The power of this technique was 
illustrated with a comprehensive assessment of unmanipulated CD4+ TR cell clonality 
directly ex vivo both in adult PBMCs and in UCBCs. While the resultant data reveal marked 
polyclonality in these CD4+ TR cell populations, potential relationships to other peripheral 
blood T cell subsets were also revealed.
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TR regulatory T cells
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TCR T-cell receptor
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Foxp3 forkhead family transcription factor P3
ICS intracellular staining
CDR3 complementarity determining region 3
TCRB the T-cell receptor Ś-chain
BV variable region of the T-cell receptor Ś-chain
BJ J-region of the T-cell receptor Ś-chain
IFN-ś interferon-ś
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Figure 1. 
CD8+ T cell populations specific for the HLA A*0201-restricted CMV pp65495– 503 antigen. 
A) Negative control (no peptide + anti-CD28/CD49d; 1 μg/ml final). B) Specific CD8+ T 
cell response following overnight stimulation with the CMV pp65495– 503 peptide. C) 
Specific CMV pp65495– 503/HLA A*0201 tetramer binding CD8+ T cells. All plots are gated 
on CD3+CD8+ cells and the sorted populations are indicated. ‘ 1’  and ‘ 2’  refer to separate 
individuals seropositive for CMV.
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Figure 2. 
Umbilical cord blood cells (left) and adult PBMCs (right) are shown gated on CD3+CD4+ T 
cells. CD25+Foxp3− (upper left gate), CD25+Foxp3+ (upper right gate) and CD25−Foxp3+ 
(lower right gate) CD3+CD4+ cells were sorted into a dry pellet and frozen at −80°C prior 
to multiplex PCR.
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Figure 3. 
A 250– 300 bp band is obtained in tubes A, B and C (right 3 lanes) following heminested 
multiplex PCR of CD4+CD25+Foxp3+ sorted cells. The 3 lanes on the left are the negative 
controls for tubes A, B and C, respectively.
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Table 1
TCRBV and TCRBJ primers used in multiplex PCR
Primer name Sequence Primer name Internal TCRBJ primers External TCRBJ primers
BV2 ATACTTCTATTGGTACAGACAAATCT BJ 1.1 CTTACCTACAACTGTGAGTCTGGTG AAAAATGTCTTACCTACAACTG
BV3 CGCTATGTATTGGTATAAACAG BJ 1.2 CTTACCTACAACGGTTAACCTGGTC CCCAGCCTTACCTACAAC
BV4 CGCTATGTATTGGTACAAGCA BJ 1.3 CTCACCTACAACAGTGAGCCAACTT TGACTTACTCACCTACAAC
BV5 CAGTGTGTCCTGGTACCAACAG BJ 1.4 CATACCCAAGACAGAGAGCTGGGTTC TCTTTTACATACCCAAGAC
BV6a ATACATGTACTGGTATCGACAAGAC BJ 1.5 CTTACCTAGGATGGAGAGTCGAGTC TTCTGCAACTTACCTAGGAT
BV6b GGCCATGTACTGGTATAGACAAG BJ 1.6 CATACCTGTCACAGTGAGCCTG GAGCCCCCATACCTGTCAC
BV6c GTATATGTCCTGGTATCGACAAGA BJ 2.1 CCTTCTTACCTAGCACGGTGA CCTGGAGCCCCCTTCTTAC
BV7a AACCCTTTATTGGTACCGACA BJ 2.2 CTTACCCAGTACGGTCAGCCT CCGCCTCCTTACCCAGTAC
BV7b AACCCTTTATTGGTATCAACAG BJ 2.3 CCCGCTTACCGAGCACTGTCA AGCCCCCGCTTACCGAGCAC
BV7c ATCCCTTTTTTGGTACCAACAG BJ 2.4 CCAGCTTACCCAGCACTGAGA GCCCCAGCTTACCCAGCAC
BV11 TACCCTTTACTGGTACCGGCAG BJ 2.5 CGCGCTCACCGAGCAC AGCCCGCGCTCACCGAGCAC
BV12a CTCCCGTTTTCTGGTACAGACAGAC BJ 2.6 CTCACCCAGCACGGTCAGCCT GCGAAAACTCACCCAGCAC
BV12b CACGGTCTACTGGTACCAGCA BJ 2.7 CTCACCTGTGACCGTGAGCCTG GCCCGAATCTCACCTGTGAC
BV14 TAACCTTTATTGGTATCGACGTGT
BV15 CGTCATGTACTGGTACCAGCA
BV18 TCATGTTTACTGGTATCGGCAG
BV19 GGCCATGTACTGGTACCGACA
BV20 AACTATGTTTTGGTATCGTCA
BV21 TTATGTTTACTGGTATCGTAAGAAGC
BV23 TTATGTTTATTGGTATCAACAGAATCA
BV25 CAAAATGTACTGGTATCAACAA
BV29 CACGATGTTCTGGTACCGTCAGCA
BV30 CAACCTATACTGGTACCGACA
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Table 2
Comparison of CD8+ T cell clonotypes specific for CMV pp65495– 503 obtained by mRNA-based PCR and DNA-based multiplex PCR
ID
mRNA clonotyping Multiplex PCR
BV CDR3 BJ BV CDR3 BJ
1
6.5 CASSYSTGTPGIYT* 1.2 6.5 CASSYSTGTPGIYT 1.2
27 CASTPAGGAPGELF** 2.2 27 CASTPAGGAPGELF 2.2
2
6.5 CASSPQTGAGRYGYT* 1.2 6.5 CASSPQTGAGRYGYT 1.2
6.5 CASSVQTGTGNYGYT** 1.2 6.5 CASSVQTGTGNYGYT 1.2
5.4 CASRVGGDTEAF 1.1 24.1 CATSPGLAGAYQETQY 2.5
4.2 CASSQESGNTEAF 1.1 29.1 CSVPGIGNIYNEQF 2.1
BV, variable region of the T-cell receptor Ś-chain; BJ, J-region of the T-cell receptor Ś-chain; CDR3, complementarity determining region 3. ID 1 and 2 represent two separate CMV-seropositive HLA 
A*0201 individuals.
*dominant clonotype
**
sub-dominant clonotype
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Table 3
T-cell receptor repertoire of UCB #1
CD4+CD25+FOXP3− CD4+CD25+FOXP3+ CD4+CD25−FOXP3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
5.4 CASSLDSPNEQY 2.7 5.4 CASSLDRASNTQY 2.3 5.4 CASSFATNSQEAQY 2.5
5.4 CASSLGEGYYGYT 1.2 5.4 CASSWGTNTGELF 2.2 5.4 CASSFGAHYTQN 2.5
5.4 CASSLGISEETQY 2.5 5.5 CASEGTVRSPLH 1.6 5.4 CASSFGAQETQY 2.5
5.4 CASSLGSSNTGELF 2.2 5.5 CASSLEITGKGSPLH 1.6 5.4 CASSLGQSPTGELF 2.2
5.4 CASSLMGLAGAAQY 2.3 5.6 CASRSGPLRRGLYEQY 2.7 5.4 CASSSAGLEEETQY 2.5
5.4 CASSLTPTENSPLH 1.6 5.6 CASSHGGTGGYT 1.2 5.6 CASRRQEYQETQY 2.5
5.4 CASSLVPETQY 2.5 5.6 CASSLEAGGTLGTDTQY 2.3 5.6 CASSLRGTLTDTQY 2.3
5.4 CASSPDRGEGYGYT 1.2 5.6 CASSLEITGKGSPLH 1.6 5.6 CASSPSPASSYNEQF 2.1
5.5 CASEGTVRSPLH 1.6 5.6 CASSLWGKGYT 1.2 6.1 CASKETGRNEQY 2.7
5.5 CASSEAGQRTETQY 2.5 6.1 CASRGLTDSRRSYNSPLH 1.6 6.1 CASRVNYEQY 2.7
5.5 CASSLDSPNEQY 2.7 6.1 CASRGTSAYNEQF 2.1 6.1 CASSAGWGSSYNSPLH 1.6
5.5 CASSLEITGKGSPLH 1.6 6.1 CASSASWGGDTQY 2.3 6.1 CASSGAPGQGQPQH 1.5
5.5 CASSLKGTGGGYGYT 1.2 6.2 CASRALYGYT 1.2 6.1 CASSPRGTSGITDTQY 2.3
5.5 CASSQQGAGELF 2.2 6.2 CASSLGWGGTNYGYT 1.2 6.1 CASSYSTNGSSSDEQY 2.7
5.5 CASSSPARDRRLSPLH 1.6 6.2 CASSSIIEQF 2.1 6.2 CASGSSLNTEAF 1.1
5.6 CASSFDRGFTDTHY 2.3 6.5 CASNDLTAKYEQY 2.7 6.2 CASSEAGNGYT 1.2
5.6 CASSLGGTANSPLH 1.6 6.5 CASSERGASTDTHY 2.3 6.2 CASSPGQGVINEQY 2.7
5.6 CASSLRTGNNEQF 2.1 6.5 CASSFPIRAGGRLTYEQY 2.7 6.2 CASSPGRTETQY 2.5
5.6 CASSLRTGNNEQF 2.1 6.5 CASSLDRVVTGELF 2.2 6.2 CASSYSARGVQY 2.3
5.6 CASSRDRGREQY 2.7 6.5 CASSYSFSRVETQY 2.3 6.2 CASSYSTSGSSSDEQY 2.7
5.6 CASSRRDSSGNTIY 1.3 6.5 CASSYSFTYWGSYEQY 2.7 6.4 CASSATGTGRIQY 2.4
5.6 CASSSPSGGTDTQY 2.3 6.5 CASTRQGHGYT 1.2 6.5 CASSRHHGGGAGELF 2.2
5.6 CASSYRGLDGYTF 1.2 6.9 CASSYSFTYWGSYEQY 2.7 6.6 CASRVNYEQY 2.7
5.8 CASKRSVGRNSPLH 1.6 11 CASRASWGEQF 2.1 6.6 CASRVNYEQY 2.7
6.1 CASSFSSGTDEQY 2.7 11 CASSLDGDRGTDTQY 2.3 6.6 CASSAGANVLT 2.6
6.2 CAGSYGYGGQNIQY 2.4 11 CASSQNIRGLAGGISDTQY 2.3 6.6 CASSPGQGVINEQY 2.7
6.2 CASSYSPFSGNYEQY 2.7 12 CASRPGGGYEQY 2.7 6.6 CASSRGWGAF 1.1
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CD4+CD25+FOXP3− CD4+CD25+FOXP3+ CD4+CD25−FOXP3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
6.2 CASSYSRFSTYSYEQY 2.7 12 CASRSGGVNYGYT 1.2 11 CASSFSRDYEQY 2.7
6.4 CASSAPDGTEAF 1.1 12 CASSFLAGSNTGELF 2.2 14 CASSQTGNSPLH 1.6
6.5 CASRTIDLETQY 2.5 12 CASSLDRVVTGELF 2.2 18 CASSKTLGGAENSPLH 1.6
6.5 CASSAIRTGGGYGYT 1.2 19 CASGQGGYNSPLH 1.6 19 CASSPTHTDTQY 2.3
6.5 CASSEAGQRTETQY 2.5 19 CASSGTWLQPQH 1.5 19 CASSTQGLYNEQF 2.1
6.5 CASSFRLRTATDTQY 2.3 19 CASSLDYGQWETQY 2.5 19 CASTKRGVPYNEQF 2.1
6.5 CASSPRGLAGHTGELF 2.2 19 CASSRFEGQETQY 2.3 19 CASTPGRGDPNYGYT 1.1
6.5 CASSYSISRVGEQY 2.7 19 CASSRTGQGDSPLH 1.6 19 CATSDHRASDTGELF 2.2
6.5 CASSYSISRVGEQY 2.7 19 CVSSGTWLQPQH 1.5 24 CATSDHRASDTGELF 2.2
6.5 CASSYSSGFRSSYNSPLH 1.6 27 CASSFSLIYNSPLH 1.6 27 CASSIQGRNQPQH 1.5
7.2 CASSLRVGPYEQY 2.7 27 CASSSQGAGANVLT 2.6 27 CASSSRGEQY 2.7
13 CASSLDGRGSREQY 2.7 29 CSLGRAGGFTDTQY 2.3 29 CSVARGNTEAF 1.1
19 CASEPGQGNSPLH 1.6 29 CSVSQTGGYGYT 1.2 30 CAWSVGLWDSPLH 1.6
19 CASRTRQGQETQY 2.5 30 CAWSGGQGPQETQY 2.5
19 CASSITPQMDQYF 2.5
19 CASSPPGPSTDTQY 2.3
19 CASTSRPGRPDTQY 2.3
24 CATSDGAGNTYNEQF 2.1
27 CASQLDYSNTGELF 2.2
27 CASSGLTYNSPLH 1.6
29 CSDGQLNTEAF 1.1
29 CSTGPRGEGRTDTQY 2.3
29 CSVAVAGKLRGDTQY 2.3
29 CSVEFLGWGGETQY 2.5
30 CAWSGGLGETQY 2.5
Bolded clonotypes are present on CD4+CD25+FOXP3− and CD4+CD25+FOXP3+ populations
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Table 4
T cell receptor repertoire of UCBC #2.
CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
5.4 CASTSPGSNYGYT 1.2 5.4 CASSPDRGSRGYT 1.2 5.4 CASSTGQGNYGYT 1.1
5.4 CASTPGGGANNSPLH 1.6 5.4 CASSQAQSNYGYT 1.2 5.4 CASSLVHTEDGYT 1.2
5.4 CASSLDFSFEQF 2.1 5.4 CASSVSTGAHGYT 1.2 5.4 CASSLRLAGHTDTQY 2.3
5.4 CASSLGAGQGTQETQY 2.5 5.4 CASSLDHNEQF 2.1 5.4 CASSLASFGEQY 2.7
5.4 CASSFGGLYEQY 2.7 5.4 CASSLKTGGGRETQY 2.5 5.4 CASSLGLFYEQY 2.7
5.4 CASSLDQYEQY 2.7 5.4 CASRPNPTSGSRYEQY 2.7 5.4 CASSLGQVHEQY 2.7
5.4 CASSLDYSYEQY 2.7 5.4 CASSALGPGKGRVAEQY 2.7 5.4 CASSWDRGDEQY 2.7
5.4 CASSLRTAYEQY 2.7 5.4 CASSLQGREQY 2.7 5.5 CASSKDRHLIGELF 2.2
5.4 CASSSRGRAYEQY 2.7 5.4 CASSWGLAGSKQY 2.7 5.5 CASSLGDTQY 2.3
5.4 CASSTKGGAGDEQY 2.7 5.5 CASSSQGTGYGYT 1.2 5.6 CASSLGPSYNSPLH 1.6
5.5 CASIKTGERTGELF 2.2 5.6 CASSLVLVNTEAF 1.1 5.6 CASSPRDTNTGELF 2.2
5.5 CASSLYGELF 2.2 5.6 CASSLEGDRDHYGYT 1.2 5.6 CASSFRVDPSTDTQY 2.3
5.5 CASSPGQGAPKTQY 2.5 5.6 CASSLVGRGNYGYT 1.2 5.6 CASSLTPGAKNIQY 2.4
5.5 CASRLGLAGVQETQY 2.5 5.6 CASRPNPTSGSRYEQY 2.3 5.6 CASSWARSGANALT 2.6
5.5 CASSPGQGAPETQY 2.5 5.6 CASSWNPDTQY 2.3 5.6 CASSLGGARVMQY 2.7
5.5 CASSLPGAGGQETQY 2.5 5.6 CASSLPGAYEQY 2.7 6.2 CASSHAGSGANVLT 2.6
5.5 CASSPGQGAPETQY 2.5 5.8 CASSFRQGANYGYT 1.2 6.2 CASSYRAVQGANVLT 2.6
5.5 CASSFSSGGLSSYEQY 2.7 6.2 CASSRDRGASGNQPQH 1.5 6.5 CASSYSEGLEAF 1.1
5.5 CASSLRTAYEQY 2.7 6.2 CASSTRSPLH 1.6 6.5 CASSFGTGWRSYGYT 1.2
5.5 CASSPGQGAPETQY 2.7 6.2 CASRGTSTDTQY 2.3 6.5 CASSYTRGIYGYT 1.2
5.6 CASSLVGTNTEAF 1.1 6.2 CASSAIDTQY 2.3 6.5 CASKLTGANSPLH 1.6
5.6 CASSFFRVEETQY 2.5 6.5 CASSVGTGGTEAF 1.1 6.5 CASSYGRQSSYNSPLH 1.6
5.6 CASRPGQGRRKETQY 2.5 6.5 CASSPGTGNYGYT 1.2 6.5 CASSYRAPLWSSPLH 1.6
5.6 CASRPGQGRRKETQY 2.7 6.5 CASSYRGGNYGYT 1.2 6.5 CASSYRQGATLH 1.6
6.1 CASISTAYNSPLH 1.6 6.5 CASRAGHPNSPLH 1.6 6.5 CASSYHYGGFQQNTH 2.5
6.2 CASSYLWEAWTVNPSNQPQH 1.5 6.5 CASSHPGQAVPLH 1.6 6.9 CASSCTEQGNSPLH 1.6
6.2 CASSYDGHQPQH 1.5 6.5 CASSTRSPLH 1.6 6.9 CASSYTEHANSPLH 1.6
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CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
6.2 CASRPGVSQGEQF 2.1 6.5 CASSWGDNSPLH 1.6 6.9 CASSYTGQGNSPLH 1.6
6.2 CASSAPRGNGYEQY 2.7 6.5 CASSLKHYNEQF 2.1 6.9 CASRVGGPDEQY 2.7
6.2 CASSFGTSGSEQY 2.7 6.5 CASSNIRASMNEQF 2.1 7.3 CASSRDLGPYEQY 2.7
6.4 CASISTAYNSPLH 1.6 6.5 CASSYSTASTDTQY 2.3 7.9 CASSLKDGREY 2.4
6.5 CASSTRPANYGYT 1.2 6.5 CASSSLAERWETQY 2.5 10 CASSERRLGLRSPPH 1.6
6.5 CASSRDRGANQPQH 1.5 6.9 CASSPGGRGLTGANVLT 2.6 11 CASSPTAGGETQY 2.5
6.5 CASRRDRGWNSPLH 1.6 6.9 CASSTSGEQY 2.7 19 CASSARQGVTPLH 1.6
6.5 CASSYSSGISGAGELF 2.2 10 CAISAAVSTSGSPLH 1.6 19 CASSTSNRGGSPLH 1.6
7.2 CASSFLGDSTDTQY 2.3 19 CASRGRTVRNSPLH 1.6 19 CASSLRGRSDNEQF 2.1
11 CASSDNRDYEQY 2.7 19 CASSQGRTNSPLH 1.6 19 CATSDHRLAGEDEQF 2.1
11 CASSLGGDSYEQY 2.7 19 CAGRRTDTGELF 2.2 19 CASSIAGGDIQY 2.4
11 CASSSRTGYEQY 2.7 19 CASSIATGSNTGELF 2.2 19 CASSVGPSAYEQY 2.7
11 CASSLISRLAGQDYEQY 2.7 19 CASSTGGKTQY 2.5 27 CASSLVGLGPLH 1.6
12 CASSSLGTGNSPLH 1.6 27 CASSLLAWGADTQY 2.3 29 CSVEITGRGGYT 1.2
19 CASRSPPNYGYT 1.2 27 CASSLYGKETQY 2.5 29 CSAQTGQGAYGELF 2.2
19 CASSSRAENSPLH 1.6 27 CASRNSGANVLT 2.6 29 CSVEEVARGGEDTQY 2.3
19 CASSIATGSNTGELF 2.2 27 CASRNSGANVLT 2.6 29 CSVPGSSGSYEQY 2.7
19 CASSIGGTQTQY 2.5 27 CASSSLGGRANVLT 2.6
24 CATSDLRRQGCYEQY 2.7 29 CSVVRGDLIEAF 1.1
24 CATSDPGAGYGEQY 2.7 29 CSVGGAIYGYT 1.2
27 CASSLLGTGDSPLH 1.6 29 CSVGLSDRGTQY 2.5
27 CASSRRWQETQY 2.5 30 CAWSFNQYNSPLH 1.6
29 CSVAGQGASNQPQH 1.5
29 CSVEKGRTGNEQF 2.1
29 CSVEQGPGETQY 2.5
29 CSVVFFSGGLGANVLT 2.6
30 CAWSEQMSYT 1.2
30 CAFIPRGSPYNSPLH 1.6
30 CAWRSQGSYNSPLH 1.6
30 CAFIPRGSPYNSPLH 1.6
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CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
30 CAWSVPRVYQETQY 2.7
Bolded clonotype is present in CD4+CD25+Foxp3− and CD4+CD25+Foxp3+ populations
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Table 5
T-cell receptor repertoire of UCB #3
CD4+CD25+FOXP3− CD4+CD25+FOXP3+ CD4+CD25−FOXP3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
4.1 CASSQWAVSSGSYEQY 2.3 5.4 CASSLSRDRGDEQF 2.1 5.3 CARSLGEQY 2.7
5.4 CASSLDSYGYT 1.2 5.4 CASSHLGETQY 2.5 5.3 CARSLTGGKQY 2.7
5.4 CASSPGHLYNSPLH 1.6 5.4 CASSLTSGGEETQY 2.5 5.4 CASSLGGGYT 1.2
5.4 CASSLIWGTDTQY 2.3 5.4 CASSGYRGINYEQY 2.7 5.4 CASSLGTDSPLH 1.6
5.4 CASSLTSSYEQY 2.3 5.4 CASSLRPAGHYEQY 2.7 5.4 CASSPTEYNEQF 2.1
5.4 CASSHLGETQY 2.5 5.4 CASSLSGSSYEQY 2.7 5.4 CASSLATGKNIQY 2.4
5.4 CASSLDRAETQY 2.5 5.4 CASSLTGGSYEQY 2.7 5.4 CASSLGRDWETQY 2.5
5.4 CASSLGGSYEQY 2.7 5.4 CASSYRGYEQY 2.7 5.4 CASSLVGAGETQY 2.5
5.4 CASSLGTSSGEQY 2.7 5.5 CASSLQGNTEAF 1.1 5.4 CASSLGEQY 2.7
5.4 CASSLTSSYEQY 2.7 5.6 CASSELAGSYNEQF 2.1 5.4 CASSPRTGGYEQH 2.7
5.5 CASSLLPVETQY 2.5 5.6 CASSPWAGAGGRRSYNEQF 2.1 5.5 CASSWLFAGPQETQY 2.5
5.6 CASSLGTSSGEQY 2.3 5.6 CASSLGSETQY 2.5 5.5 CASSPPSGGAETQY 2.7
5.6 CASSLWSGSRVSDTQY 2.3 5.6 CASSFLQYEQY 2.7 6.2 CASTDNRTPNSPLH 1.6
5.6 CASSLLPVETQY 2.5 6.1 CAGRPRVGETQY 2.5 6.4 CASTRLAGGYNEQF 2.1
6.5 CASSELDYEQY 2.7 6.2 CATSTSGNEQF 2.1 6.5 CASSQGYGYT 1.2
10.2 CASKTILYNEQF 2.1 6.2 CASSPDRGQWAGGTQY 2.3 6.5 CASSRDTNYGYT 1.2
11.2 CASRLAGVRDNEQF 2.1 6.2 CASSYSTTDINTDAQY 2.3 6.5 CASSYSSRDNYGYT 1.2
12.5 CASGLVLQGKVFGYT 1.2 6.2 CASSYEYRGGYEQY 2.7 6.5 CASRQGMQPQH 1.5
19 CASTEQGAIWNSPLH 1.6 6.2 CASSYSTGVRYEQY 2.7 6.5 CASSLNLLAITYNEQF 2.1
24.1 CATKPGQGANSPLH 1.6 6.5 CASSYGGLYGYT 1.2 6.5 CASVRDNYNEQF 2.1
27 CASSFSSYNSPLH 1.6 6.5 CASIEQTVGGLNQPQH 1.5 6.5 CASRDAVPDTQY 2.3
27 CASSLYNSPLH 1.6 6.9 CASSYQPRHLAKNIQY 2.4 6.5 CASSYLAGASEQY 2.7
29.1 CSVGGNTEAF 1.1 11.2 CASSLGTGGEQY 2.7 6.5 CASSYQGQRSYEQY 2.7
29.1 CSVVVRQNRTALYGYT 1.2 12.3 CASSLERQGARYEQY 2.7 6.5 CASSYRGRRSYEQY 2.7
29.1 CSVEEGTGGYEQY 2.7 19 CASSILQDNSPLH 1.6 6.5 CASSYSLKLTSAYEQY 2.7
19 CASSIRYNSPLH 1.6 19 CASSIGSKETQY 2.5
19 CASSRDRGSPLH 1.6 29.1 CSARPYATDTQY 2.3
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CD4+CD25+FOXP3− CD4+CD25+FOXP3+ CD4+CD25−FOXP3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
19 CASSRTGGADTQY 2.3 29.1 CSVESPGGYEQY 2.7
19 CASSIDRTGGAETQY 2.5 29.1 CSVQGQLYEQY 2.7
19 CASSIGKTQY 2.5
19 CASSMDRGTYEQY 2.7
27 CASSLSGQGYNSPLH 1.6
27 CASSGGGRRGDTQY 2.3
29.1 CSVRGTTRPNYGYT 1.2
29.1 CSVDFTGEVTDTQY 2.3
29.1 CSVEGLSGIGTDTQY 2.3
29.1 CSGTGITYEQY 2.7
29.1 CSVSTGGYEQY 2.7
Bolded clonotype is present on CD4+CD25+FOXP3− and CD4+CD25+FOXP3+ populations
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Table 6
T-cell repertoire of PBMCs #1
CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
5.3 CARRPGQGSYEQY 2.7 5.4 CASSLGGVGTEAF 1.1 5.4 CASSANLRDRGNTGELF 2.2
5.4 CASSATISNEQF 2.1 5.4 CASSPTGTGGYGDTEAF 1.1 5.4 CASSFIEDTGELF 2.2
5.4 CASSFPRGVNTGELF 2.2 5.4 CASSVRLAGGTTDTQY 2.3 5.4 CAAGTSQETQY 2.3
5.5 CASSTGYEQY 2.7 5.4 CASSWTTWSDYGYT 1.2 5.4 CASSLGTGANVLT 2.6
5.6 CASSLGGRPDTQY 2.3 5.5 CASSLYSFYEQY 2.7 5.4 CASSLGSYEQY 2.7
5.6 CASSLVGGHTEAF 1.1 5.5 CASSRLYEQY 2.7 5.6 CASSQTGTAYEQY 2.7
5.6 CASSRGPVNTEAF 1.1 5.5 CASSWDRDEQY 2.7 6.5 CASSETGTRRSPLH 1.6
5.6 CASSRTGTSGSHEQY 2.7 5.6 CASSAWSSYNSPLH 1.6 6.5 CASSYAHPGQANSPLH 1.6
5.6 CASSSPGQVNSPLH 1.6 5.6 CASSLGGTYTQY 2.3 6.5 CASSYPSLAGGQGSYNEQF 2.1
5.6 CASSSVGVKTQY 2.5 5.6 CASSLYSFYEQY 2.7 6.5 CASSYSGLAGGTDTQY 2.3
6.5 CASSLGGRPDTQY 2.3 5.6 CASSPGVAGRNQETQY 2.5 6.5 CASSYSHGVSLL 2.3
6.5 CASSQTSGRRGNEQF 2.1 5.6 CASSPLSSMNTEAF 1.1 6.5 CASSYSMLGRSTDTQY 2.3
6.5 CASSRGREPTYEQY 2.7 5.6 CASSRLYEQY 2.7 6.5 CASSQPRVRRRY 2.7
6.5 CASSSGLAGLQETQY 2.5 6.1 CASSDRSGSKYEQF 2.1 6.6 CACSLRGDYGYT 1.2
6.5 CASSSPGQVNPPLH 1.6 6.1 CASSEGVANTGELF 2.2 11.3 CASSTRGRLNSPLH 1.6
6.5 CASSSQVNNSPLH 1.6 6.1 CASSLLGKGEQF 2.1 11.3 CASSLGTGANVLT 2.6
6.5 CASSYGLAGADTQY 2.3 6.2 CASSDRSGSKYEQF 2.1 11.3 CASSLRDSSYEQY 2.7
6.9 CASNKRDSTYEQY 2.7 6.2 CASSYSSGTSGRNEQY 2.7 24.1 CATSDRTGNGYEQY 2.7
7.9 CATPDVTGESGANVLT 2.6 6.4 CASRKTVNTEAF 1.1 28 CASSPWGFTLH 1.6
11.2 CASSLVRLARGDTQY 2.1 6.5 CASSLLGKGEQF 2.1 29.1 CSVEGWVTEAF 1.1
11.3 CASRRSGTRRSQETQY 2.5 6.5 CASSPPQGTGGYT 1.2 29.1 CSVGLGGVASEAF 1.1
11.3 CASSAGLAGGLSSYEQY 2.7 6.5 CASSYSIHADTQY 2.3 29.1 CSVEQGRQPQH 1.5
11.3 CASSLGAGGGETQY 2.5 6.5 CASTSQGIYEQY 2.7 29.1 CSVDYRALYNEQF 2.1
11.3 CASSLGCTSGICEETQY 2.5 10 CASSVWTSGRLYEQY 2.7 29.1 CSVEMVGGRETQY 2.3
11.3 CASSLRWQIEQF 2.1 10 CAIAPRSLRYNEQF 2.1 29.1 CSVKQLAAETQY 2.3
11.3 CASSLTGGFSPLH 1.6 10 CAISGSGVTDTQY 2.3 29.1 CSIALGSDNQETQY 2.5
11.3 CASSLVRLARGDTQY 2.3 11 CASSLRWDRVYEQY 2.7 29.1 CSVALGSDNQETQY 2.5
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CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
12.3 CASSLGWQGPLH 1.6 11 CASSLEWTGGTYEQY 2.7 29.1 CSVEMVGGRETQY 2.5
27 CASKTGRGGANVLT 2.6 12 CASSLTSGSPLYPSSYEQY 2.7 29.1 CSVKQLAAETQY 2.5
27 CASSFLPRLGNSPLH 1.6 19 CASSRKPRSGVVSYEQY 2.7 29.1 CSGVTASSGEAYEQY 2.7
29.1 CSVDRGLMETQY 2.5 19 CATSESGTGITGELF 2.2 29.1 CSVGQGAVYEQY 2.7
29.1 CSVEKGSYEQY 2.7 19 CVSSRKPRSGVVSYEQY 2.7
29.1 CSVGKGLSNTEAF 1.1 24 CATSDASGSYTDTQY 2.3
29.1 CSVGYRPNTEAF 1.1 24 CATSEAGPLDTQY 2.3
29.1 CSVIWGGYEQY 2.7 27 ASRPQGLLSTDTQY 2.3
29.1 CSVRLQSGETQY 2.5 27 CASRPQGLLSTDTQY 2.3
29.1 CSVSGTGGPVRSEQY 2.7 27 CASRPQGLVSTDTQY 2.3
29.1 CSVVPGNQETQY 2.5 27 CASSPTAGLEAF 1.1
27 CASSSLREGSDTQY 2.3
29 CSSIGGTTSGISYNEQF 2.1
29 CSVETVSIWAADRANYGYT 1.2
29 CSVGGTRRNYGYT 1.2
29 CSVKRGGTGGFEQY 2.7
29 CSVVGQGLSEQY 2.7
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Table 7
T cell receptor repertoire of PBMC #2.
CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
5.4 CASSAQGRSPLH 1.6 5.4 CASSLARGRAHNEQF 2.1 5.4 CASSLRALSFGYT 1.2
5.4 CASSLGSVSGANVLT 2.6 5.4 CASSLGQGVYNEQF 2.1 5.4 CASSQLTDGYT 1.2
5.4 CASSFPLLEQY 2.7 5.4 CASSLALAGVTGELF 2.2 5.4 CASSLKGHYSPLH 1.6
5.5 CASSLEREQF 2.1 5.4 CASSLGLAGGADMQY 2.3 5.4 CASLVQGAETQY 2.5
5.6 CASTQNTEAF 1.1 5.4 CASSLGLAGGADTQY 2.3 5.4 CASTSRGPETQY 2.5
5.6 CASSWGGGRHSSYEQY 2.7 5.4 CASGFTQETQY 2.5 5.4 CASSLDEGQGWSYEQY 2.7
6.1 CASDAWDEQF 2.1 5.4 CASSFPLLEQY 2.7 5.5 CASSLQGSYGYT 1.2
6.1 CASSELIPGLPDGNEQF 2.1 5.4 CASSLDIAGFYEQY 2.7 5.6 CASSFVGRDSPLH 1.6
6.1 CASSPSTSGSNEQF 2.1 5.5 CASSFGRINQPQH 1.5 5.6 CASSLKGHYSPLH 1.6
6.1 CASSYRRRTSPGELF 2.2 5.6 CASSLQFGQAYEQY 2.7 5.6 CASSLRTSGKSDTQY 2.3
6.2 CASRDRGLRDEQF 2.1 6.5 CASSLTGSNYGYT 1.2 5.6 CASSLWGSETQY 2.5
6.4 CASSRPFPYY 2.7 6.5 CASSYNFGNTGELF 2.2 5.6 CASSPDRGETQY 2.5
6.5 CASSLGDGANTIY 1.3 6.5 CASSYNFGNTGKLF 2.2 6.5 CASSYGGGGRPQH 1.5
6.5 CASSYSTRTGLGNTIY 1.3 6.5 CASSYTGAANTGELF 2.2 6.5 CASSYSGARYNSPLH 1.6
6.5 CASRQAHYNSPLH 1.6 6.5 CASGFTQETQY 2.5 6.5 CASSRRLGATSRIHEQY 2.7
6.5 CASSELIPGLPDGNEQF 2.1 6.5 CASRNQREPCEQY 2.7 6.5 CASSYWDSPYEQY 2.7
6.5 CASSPPQRDRADTQY 2.3 6.5 CASSYSRLAGYEQY 2.7 6.5 CASTHRVGHEQY 2.7
6.5 CASKLAGAGETQY 2.5 7.8 CASSSSAGNEQF 2.1 6.7 CASTGSTDTQY 2.3
11.1 CASSDSELAGGKGMEF 2.1 12.3 CASSHRTGLLNSPLH 1.6 7.3 CASSPGGPNEQF 2.1
11.2 CASSTGLQETQY 2.5 18 CASSREEGEQY 2.7 7.9 CASREMGNSPLH 1.6
19 CASIGRAGVLQPQH 1.5 19 CASSTRNSPLH 1.6 13 CASSFVGRDSPLH 1.6
19 CATSETHGNTGELF 2.2 19 CASSAPRQGSYNEQF 2.1 19 CASSINTGTSCGYT 1.2
19 CASSILGTEETQY 2.5 19 CASSSQGSTDTQY 2.3 19 CASSGQLNQPQH 1.5
27 CASSLSLVGAGGPNTQY 2.3 19 CASSILQGWETQY 2.5 24.1 CATSDSGQGGNSPLH 1.6
29.1 CSVEGQAFDISYNSPLH 1.6 19 CASSWDKIRGETQY 2.5 27 CASSDSQTSGSNEQF 2.1
29.1 CSGRLAGVNEQF 2.1 24.1 CATSDSYGYT 1.2 27 CASRPQGRETQY 2.5
29.1 CSVLGLAGVKQF 2.1 29.1 CSVGGEKLF 1.4 29.1 CSVGEGGGYT 1.2
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CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
29.1 CGVVPLGGMGETQY 2.5 29.1 CSVEDLGPF 2.1 29.1 CSVDPTGGSEKLF 1.4
29.1 CSVVTDSYEQY 2.7 29.1 CSVVWTGLTGELF 2.2 29.1 CSVEDLGPF 2.1
30 CASRPRSSYNSPLH 1.6 29.1 CSVEVGAGKTQY 2.5 29.1 CSVERQGRAGELF 2.2
30 CAWEGTVNSPLH 1.6 30 CAWSAGTGVNSPLH 1.6 29.1 CSVIRGSGANVLT 2.6
30 CAWGRGGYNSPLH 1.6 29.1 CSVGVGQGAYEQY 2.7
30 CAWGEWEQF 2.1
30 CACRDRQETQY 2.5
30 CAWNSPARSQETQY 2.5
30 CAWRDRDIVNSGANVLT 2.6
Bolded clonotype is present on CD4+CD25+Foxp3− and CD4+CD25+Foxp3+ populations
Underlined clonotype is present on CD4+CD25+Foxp3+ and CD4+CD25−Foxp3+ populations
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Table 8
T-cell repertoire of PBMC #3
CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
5.3 CASTLDSSYNEQF 2.1 5.4 CASSAEGTSGYT 1.2 5.1 CASSLESGSGRD 2.7
5.4 CARIRTRGQGDRCEQY 2.7 5.4 CASSIGQAAASPLH 1.6 5.4 CASSLALGRNPPYNEQF 2.1
5.4 CASSLDISGANVLT 2.6 5.4 CASSLAGQRPEY 2.7 5.4 CASSPSLAVAQDTQY 2.3
5.4 CASSLGQLSYNEQF 2.1 5.4 CASSLEPRTGEAGYT 1.2 5.5 CASSLVGRGEEGYT 1.2
5.4 CASSLRTRSVGEQY 2.7 5.4 CASSPGGLAGYEQY 2.7 6.2 CAIRGFSSNYGYT 1.2
5.4 CASSPGFLAGGRETQY 2.5 5.4 CASSSITNGYT 1.2 6.2 CASNQALAGADTQY 2.3
5.4 CASSPPDDGQETQY 2.5 5.4 CASTLEPRTGEAGYS 1.2 6.2 CASQLGGTPSNYGYT 1.2
5.4 CASTPRGGSDTQY 2.3 5.5 CASRSTQETQY 2.5 6.5 CASGLGGLASPLH 1.6
5.4 CASTPRGGSDTQY 2.3 5.5 CASSLEPRTGEAGYT 1.2 6.5 CASSGSQTGKGDEQY 2.7
5.5 CASSFGDTSGANVLT 2.6 5.5 CASSLRGQYEQY 2.7 6.5 CASSRGLAGVPETQY 2.5
5.5 CASSLDGQYSGNTIY 1.6 5.5 CASSLSGTLSSYNSPLH 1.6 6.5 CASSYDRGINSPLH 1.6
5.5 CASSLRTRSVGEQY 2.7 5.5 CASSRRQGGENSPLH 1.6 6.5 CASSYQGVGRYEQY 2.7
5.6 CAGSFGDTSGANVLT 2.6 5.5 CASSSLGTAINSPLH 1.6 6.5 CASSYRRGGSYEQY 2.7
5.6 CASRRVGGIYEQY 2.7 5.5 CASSWDGNYGYT 1.2 6.5 CASSYSFYNGYT 1.2
5.6 CASSFGDTSGANVLT 2.6 5.6 CASSERQARRGYT 1.2 6.6 CASSYSQGAGADTQY 2.3
5.6 CASSPPSGASYEQY 2.7 5.6 CASSLEQTYEQY 2.7 7.9 CASSSTRTQY 2.5
5.8 CASSLVGLTYEQY 2.7 5.6 CASSLERGLYNEQF 2.1 11.3 CASSLGTSGILRGETQY 2.5
6.1 CAGSSSGGSNSPLH 1.6 5.6 CASSRPQVNNEQF 2.1 11.3 CASSSGTSGILRGETQY 2.5
6.1 CASRWDGSYSPLH 1.6 5.6 CASSRRQGGENSPLH 1.6 12.3 CASSRDMLPQPQH 1.5
6.1 CASSESVRGGRYNEQF 2.1 5.6 CASSRTGLETQY 2.5 18 CASSDREGSPLH 1.6
6.1 CASSSSGGSNSPLH 1.6 6.1 CAISERDPSSYNSPLH 1.6 18 CASSPTGSRDSPLH 1.6
6.5 CASRTSGWAYNEQF 2.1 6.1 CASGSTGVSYNSPLH 1.6 24.1 CATSDPSPLTGGAETQY 2.5
6.5 CASSYLRTGGGYGYT 1.2 6.1 CASRGTGLSPLH 1.6 24.1 CATSDSSGGNNEQF 2.5
11.2 CASSLEMGDGDYEQY 2.7 6.1 CASRPGTGFSWDSPLH 1.6 27 CAGSDREGSPLH 1.6
18 CASSLAGGREETQY 2.5 6.1 CASRTTSGRKRNEQF 2.1 27 CASGVRGNSPLH 1.6
19 CAAGQSSYNSPLH 1.6 6.1 CASSPLVGVYNEQF 2.1 27 CASRTSGSGFSGANVLT 2.6
19 CASRPGQRERGYT 1.2 6.4 CASSDVPDRARNTEAF 1.1 27 CASSDREGSPLH 1.6
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CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
19 CASRQGLGTGELF 2.2 6.5 CASRGTTFEQF 2.1 27 CASSLEQYNSPLH 1.6
19 CASSLGLAGNYEQY 2.7 6.5 CASSPLRGRVFYEQY 2.7 27 CASSLWDRITDTQY 2.3
19 CASSNLAGEGETQY 2.5 6.5 CASSPSYSPDNEQF 2.1 27 CASSPTGSRDSPLH 1.6
19 CASSVMTGVGNSPLH 1.6 6.5 CASSSPTRLVYEQY 2.7 29.1 CSVSTSLDRVKEQY 2.7
24.1 CATSDAAEVGETQY 2.5 6.5 CASSYSPRGPPYEQY 2.7 29.1 CSVTQGLYGYT 1.2
24.1 CATSDRAGLGDEQF 2.1 6.5 CASTHRQGANYHY 2.7 29.1 CSVVWGDGYT 1.2
24.1 CATSGNSGSQNIQY 2.4 6.9 CASTTPGLAGGSSYNEQF 2.1 30 CAWSGLARDGELF 2.2
24.1 CATSGSSGSQNIQY 2.4 11.1 CASSLSGTLSSYNSPLH 1.6
27 CASSYSRGTGGDSPLH 1.6 11.1 CASSSRAQGHEQY 2.7
29.1 CSPSGELF 2.2 11.3 CASRPGLGRGTQY 2.5
29.1 CSVDQTSGATDTQY 2.3 11.3 CASSLILGRETQY 2.5
29.1 CSVEGRTSGSTRTQY 2.3 11.3 CASSLRGSGTYEQY 2.7
29.1 CSVENRGDPGANVLT 2.6 11.3 CASSSYYNSPLH 1.6
29.1 CSVGFSEDSPLH 1.6 19 CASSELAGGLGNEQF 2.1
29.1 CSVGTDTQY 2.3 19 CASSIAFRGYQAGGANVLT 2.6
19 CASSIDLSRTSARTDTQY 2.3
19 CASSLPTGTGLNSPLH 1.6
19 CASSPGLVAGVGETQY 2.5
19 CASSPGTFLPNSPLH 1.6
19 CASSPGTGLGRNEQF 2.1
19 CATRTQSLTRANTGELF 2.2
24.1 CATSDLGGYT 1.2
24.1 CATSDSPRTSLVRETQY 2.5
24.1 CATSDTGHPQETQY 2.5
27 CASSLGLGGTDTQY 2.3
27 CASSPQRSYGYT 1.2
29.1 CSATGQLNTEAF 1.1
29.1 CSGGRTVLSGEAF 1.1
29.1 CSGRMGQATEAF 1.1
29.1 CSVDEGNTGELF 2.2
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CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
29.1 CSVDGTRGDTDTHY 2.3
29.1 CSVDRGKGNYGYT 1.2
29.1 CSVEGRGRGVTEAF 1.1
29.1 CSVEPVGGSGAYEQY 2.7
29.1 CSVLGQAPSSYEQY 2.7
29.1 CSVQPVGGSGAYEQY 2.7
29.1 CSVVQPSGTSGKETQY 2.5
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Table 9
Shared clonotypes between CD4+CD25+Foxp3+, CD4+CD25+Foxp3− and CD4+CD25−Foxp3+ populations
CD4+CD25+Foxp3− CD4+CD25+Foxp3+ CD4+CD25−Foxp3+
BV CDR3 BJ BV CDR3 BJ BV CDR3 BJ
PBMC 1 ---------- ---------- ----------
PBMC 2 5.4 CASSFPLLEQY 2.7 5.429.1
CASSFPLLEQY
CSVEDLGPF
2.7
2.1 29.1 CSVEDLGPF 2.1
PBMC 3 ---------- ---------- ----------
UCBC 1 5.55.5
CASEGTVRSPLH
CASSLEITGKGSPLH
1.6
1.6
5.5
5.5
CASEGTVRSPLH
CASSLEITGKGSPLH
1.6
1.6 ----------
UCBC 2 19 CASSIATGSNTGELF 2.2 19 CASSIATGSNTGELF 2.2 ----------
UCBC 3 5.4 CASSHLGETQY 2.5 5.4 CASSHLGETQY 2.5 ----------
PBMC, peripheral blood mononuclear cells; UCBC, umbilical cord blood cells, BV, variable region of the T-cell receptor Ś-chain; BJ, J-region of the T-cell receptor Ś-chain; CDR3, complementarity 
determining region 3
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